1. RP is rare, but not ultra-thin
HD can generate even higher value per patient, yet its patient pool is materially thinner. RP benefits from a larger accumulated global prevalent population.
This page has been rebased to the April 24, 2026 document. RP is modeled through an R&D-capital / pipeline-valuation proxy: it starts from an observable public-capital-footprint midpoint of about $4.52B in 2026 and extends that base to 2036 with an 7.2% CAGR. The objective is practical: to assess whether RP still merits sustained drug R&D commitment and whether this capital-formation path can plausibly become a roughly $9B asset pool within a decade.
Note: in this revision, the RP 2026 R&D-capital / pipeline-valuation proxy midpoint is set at $4.52B; all 2036 RP figures are then extended at 7.2% CAGR. This is not a treatment-sales TAM and should not be read as a de-duplicated asset EV.
The RP commercial thesis rests on a global patient pool of roughly 1.5-2.0 million, severe unmet need, high-value one-time interventions, and mutation-agnostic platforms that expand treatable populations beyond narrow genotype subsets. Both NEI and Foundation Fighting Blindness describe the global RP population in the ~1.5-2.0 million range[S1][S2].
HD can generate even higher value per patient, yet its patient pool is materially thinner. RP benefits from a larger accumulated global prevalent population.
This revision starts from an observable RP capital-footprint midpoint of about $4.52B in 2026 and extends it at an 7.2% CAGR. That yields roughly $9.06B in 2036. This is a capital-formation proxy rather than a treatment-sales TAM; under the conservative de-duplicated RP asset-value view, the 2036 range is approximately $4.0B-$6.0B.
Within the roughly $9.06B RP R&D-capital / pipeline-value proxy, the largest increment is still expected to come from mutation-agnostic gene therapy, optogenetics, and cell therapy. That is the key reason RP can sustain more capital depth than very narrow single-gene categories.
RP has been formally recognized in China’s rare disease framework, and recent policy moves have strengthened communication pathways, conditional approval, priority review, data protection, and market exclusivity[S5][S6][S7][S9][S10].
This chart no longer plots the 2036 extrapolation. Instead, it starts with the first visible RP asset-pricing event and rebuilds the historical path into 2026 from publicly disclosed financings, upfront deal payments, and comparable valuation anchors. Hovering over each yearly node reveals the financing events that appeared in that year and their shares of that year's incremental capital signal.
The line shows the year-end RP capital-footprint path after normalizing public capital events; the 2026 endpoint is fixed to the current main-report midpoint of $4.52B.
The curve begins in 2019 because that is the earliest year in the current scope with a directly quotable RP asset-pricing event, namely the Meira / Janssen upfront around bota-vec.
Each year's disclosed financings, upfront deal payments, and comparable valuation anchors first form an annual capital signal, then the cumulative path is normalized back to the current 2026 RP pipeline midpoint of about $4.52B.
The percentages shown in the tooltip reflect each event's share of that year's incremental capital signal. Undisclosed events are retained in notes but excluded from percentage math.
The historical curve shows that RP capitalization did not emerge all at once. It built stepwise from a single transaction anchor into a multi-platform financing field between 2019 and 2026.
That page expands the public capital-event tables, stage-by-stage pipeline inventory, valuation bridge, key case notes, and diligence gaps. It is the natural next stop after reading the historical capitalization curve.
This version expands the map to include RP alongside AMD, glaucoma, stroke, AD, PD, and a broader set of rare diseases including ALS, SMA, DMD, Pompe disease, Gaucher disease, Fabry disease, and sickle cell disease. The top-left toggle switches between 2026 current scale and 2036 forecast scale. The chart uses a single-bubble view in which bubble area represents the corresponding market scale or capital-footprint scale. RP uses an observable R&D-capital / pipeline-value proxy; comparator diseases mostly use public treatment-market or commercial-opportunity metrics. It should therefore be read as a comparison of value density, not as a fully homogeneous treatment-sales TAM ranking.
The current view rebuilds 2036 scale from 2026 baselines and disease-level CAGR, together with 2036 patient counts. Both axes are transformed with log10 scaling. For RP, the chart follows a path of $4.52B observable public capital footprint in 2026 + 7.2% CAGR, implying about $9.06B in 2036.
Under the revised scope, the chart is more directly about capital formation and value density. RP still stands clearly above AMD, glaucoma, AD, and PD on value density, while sitting in a credible upper-mid band versus high-paying rare-disease categories.
On an R&D-capital / pipeline-value proxy basis, RP reaches about $9.06B by 2036. The investment case continues to rest on durable capital formation, broad-platform leverage, and re-rating as the field moves toward registration.
The ranking bars complement the Bubble Map and make it easier to locate RP versus both rare ophthalmology peers and high-paying rare disease categories.
| Disease | 2036 Scale / Value | 2036 Patient Count | Market Value per Patient | Market / Patient Scope |
|---|
What is split here is the approximately $9.06B RP R&D-capital / pipeline-value proxy. Within that pipeline layer, this report assumes: mutation-agnostic gene therapy / optogenetics 41%, genotype-specific replacement / editing 24%, cell therapy 16%, neuroprotection and maintenance drugs 13%, and BCI / implantable vision restoration 6%.
Warmer colors indicate the core RP revenue stack; cooler colors represent later-stage restoration or supportive recovery layers.
RP is genetically heterogeneous. Narrow genotype-specific projects can create meaningful assets, but broad platforms unlock a much larger commercial pool.
They retain high pricing power, clear biological rationale, and a strong reimbursement narrative, especially in well-defined genetic subtypes with observable natural history.
Cell therapy addresses patients who still retain retinal structure but have already lost substantial function. That creates a partially distinct commercial segment rather than a simple overlap with gene therapy.
These assets may be less dramatic from a narrative standpoint, yet they are well suited to long-term maintenance, combination use, and earlier-stage penetration.
BCI is primarily relevant to very late-stage patients with irreversible structural loss. It carries higher technical and reimbursement complexity and is more appropriately modeled as a supplementary high-value layer.
RP often begins in childhood or early adulthood and accumulates over many years, creating a large prevalent patient pool. That structure is especially supportive for one-time treatment economics.
The broad BCI market is publicly projected at roughly $13.9B in 2035 and approximately $16.1B in 2036 on a one-year CAGR extension[S20]. The portion directly attributable to RP is modeled here at only about $0.54B. That is still only about 6% of RP’s 2036 R&D-capital / pipeline-value proxy. Even the more comparable public bionic-eye / visual-prosthesis market remains a secondary layer rather than the core RP value pool[S21].
All three sit under “vision restoration,” but BCI remains only a small slice of the total RP opportunity.
If the goal is to build conviction in RP drug development, BCI should be framed as an additive late-stage technology layer. The core commercial logic of RP remains biologic therapy-led.
The highest strategic priority still lies in broad gene therapy, optogenetics, and cell therapy because they address wider patient populations, fit clearer reimbursement pathways, and carry larger revenue potential.
The important point is the emerging continuity across disease recognition, development-methodology guidance, conditional approval, priority review, data protection / market exclusivity, and payment. This strengthens the case for China as an independent commercial region capable of supporting meaningful peak sales.
This is the revised base-case range for China’s RP value pool in 2036, equivalent to roughly 10%–15% of the global total. Even under the RP R&D-capital / pipeline-value proxy, China alone could still support a meaningful second growth curve for a first-in-class broad RP therapy.
Three factors matter most for commercialization in China. First, RP is now embedded within the formal rare disease recognition framework, which supports coordination across patient groups, hospitals, regulators, and payers[S5]. Second, CDE has opened consultation on model-informed rare-disease drug development, while the drug-registration framework and priority-review service pages continue to keep rare-disease products within conditional approval and priority-review pathways, reducing uncertainty around small-sample development and registration timing[S6][S7][S8]. Third, 2025-2026 policy design formally incorporated market exclusivity of up to 7 years and data protection of up to 6 years, which is supportive for original-drug profitability and valuation durability[S9][S10].
In addition, the latest official communication indicates that roughly 100 rare-disease drugs are now included in China’s national reimbursement list, signaling a continued rise in payer willingness to absorb rare-disease innovation[S11]. That is a constructive signal for future RP therapies entering commercial insurance, local supplemental reimbursement, charitable access programs, and other innovative payment structures.
The estimates below are derived from “peak treated patients × net realized price × sustainable penetration × operating margin”. Within a 2036 RP R&D-capital / pipeline-value proxy of about $9.06B, a broad RP original asset with genuine platform utility could still plausibly support $0.75B-$1.70B peak sales and $0.23B-$0.64B annual operating profit.
| Original Asset Type | Peak Net Price | Peak Annual Treated Patients | Peak Sales | Operating Margin | Annual Operating Profit |
|---|
This report separates external inputs into two layers: hard-source evidence, including policy documents, epidemiology, and public market forecasts; and model-based inference, including the 2036 base-case market size, modality split, and single-asset profit pool. Model outputs are intentionally kept around conservative-to-mid-range values.
[S1] National Eye Institute, Retinitis Pigmentosa. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/retinitis-pigmentosa[S2] Foundation Fighting Blindness, Retinitis Pigmentosa. https://www.fightingblindness.org/diseases/retinitis-pigmentosa[S3] IMARC Group, Retinitis Pigmentosa Market. https://www.imarcgroup.com/retinitis-pigmentosa-market[S4] Market.us, Retinitis Pigmentosa Market. https://market.us/report/retinitis-pigmentosa-market/[S5] Chinese Government, First Batch Rare Disease List. https://www.gov.cn/gongbao/content/2018/content_5313433.htm[S6] CDE, public consultation on model-informed rare-disease drug development guidance. https://www.cde.org.cn/main/news/viewInfoCommon/87de56f0f07d1c31eaf17bd0d4f23f4d[S7] CDE, interpretation of conditional-approval provisions in the Drug Registration Measures. https://www.cde.org.cn/main/news/viewInfoCommon/4f11a8fcf086e8de5d6cd2b9ce485d2c[S8] CDE, priority review and approval procedure service page. https://www.cde.org.cn/main/guide/contentpage/545cf855a50574699b46b26bcb165f32[S9] Chinese Government, opinion on deepening drug and medical-device regulatory reform to promote high-quality pharmaceutical development. https://www.gov.cn/zhengce/zhengceku/202501/content_6996117.htm[S10] Official repost of the Implementation Regulation of the Drug Administration Law (State Council Order No. 828). https://www.mee.gov.cn/ywgz/fgbz/fl/202601/t20260108_1100338.shtml[S11] Chinese Government infographic, roughly 100 rare-disease drugs now covered by reimbursement. https://www.gov.cn/zhengce/jiedu/tujie/202509/content_7041587.htm[S12] Wong et al., Global prevalence of age-related macular degeneration. https://doi.org/10.1016/S2214-109X(13)70145-1[S13] OMR Global, Glaucoma Treatment Market. https://www.omrglobal.com/industry-reports/glaucoma-treatment-market[S14] Tham et al., Global prevalence of glaucoma and projections to 2040. https://doi.org/10.1016/j.ophtha.2014.05.013[S15] WHO, Dementia fact sheet. https://www.who.int/news-room/fact-sheets/detail/dementia[S16] GlobeNewswire / Research and Markets, Alzheimer's Drugs Global Market Research Report 2025-2033. GlobeNewswire article[S17] BMJ, Future projections on global Parkinson's disease burden. https://www.bmj.com/content/388/bmj-2024-080952[S18] IMARC Group, Parkinson's Disease Treatment Market. https://www.imarcgroup.com/parkinsons-disease-treatment-market[S19] IMARC Group, Huntington's Disease Treatment Market. https://www.imarcgroup.com/huntingtons-disease-treatment-market[S20] Precedence Research, Brain Computer Interface Market. https://www.precedenceresearch.com/brain-computer-interface-market[S21] IMARC Group, Bionic Eye Market. https://www.imarcgroup.com/bionic-eye-market[S22] IMARC Group, Ischemic Stroke Market. https://www.imarcgroup.com/ischemic-stroke-market[S23] IMARC Group, Brain Hemorrhage Market. https://www.imarcgroup.com/brain-hemorrhage-market[S24] IMARC Group, Amyotrophic Lateral Sclerosis Treatment Market. https://www.imarcgroup.com/amyotrophic-lateral-sclerosis-treatment-market[S25] IMARC Group, Spinal Muscular Atrophy Market. https://www.imarcgroup.com/spinal-muscular-atrophy-market[S26] IMARC Group, Duchenne Muscular Dystrophy Drugs Market. https://www.imarcgroup.com/duchenne-muscular-dystrophy-drugs-market[S27] IMARC Group, Pompe Disease Treatment Market. https://www.imarcgroup.com/pompe-disease-treatment-market[S30] IMARC Group, Gaucher Disease Market. https://www.imarcgroup.com/gaucher-disease-market[S31] IMARC Group, Fabry Disease Market Report. https://www.imarcgroup.com/fabry-disease-market-report[S32] IMARC Group, Sickle Cell Disease Treatment Market. https://www.imarcgroup.com/sickle-cell-disease-treatment-market[S35] GBD / Lancet Haematology, global sickle cell disease prevalence. https://pubmed.ncbi.nlm.nih.gov/36087629/[S36] Duchenne muscular dystrophy prevalence review. https://pmc.ncbi.nlm.nih.gov/articles/PMC5772123/[S37] Systematic review on SMA prevalence. https://pmc.ncbi.nlm.nih.gov/articles/PMC8548335/[S38] Fabry disease epidemiology review. https://pmc.ncbi.nlm.nih.gov/articles/PMC6852505/[S39] Orphanet, Gaucher disease prevalence. https://www.orpha.net/en/disease/detail/355[S40] ALS epidemiology review. https://pmc.ncbi.nlm.nih.gov/articles/PMC7813222/[S41] IMARC Group, Macular Degeneration Treatment Market. https://www.imarcgroup.com/macular-degeneration-treatment-market